Fig. 2
From: Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease
Validation of ELISA specific for total α-syn. a Histograms representing the optimization of the capture antibody (Syn-140) concentration. Based on the sensitivity and background signal (BG), 0.1 μg/ml of the capture antibody was selected for subsequent assays. b Standard curves displaying the specificities and sensitivities for α- (♦), β- (■) and γ-syn (▲). c Data shown are representative of 3 independent experiments using serial dilutions of recombinant α-syn freshly prepared over 3 non-consecutive days. Measurements were taken in duplicate, and the results show the mean ± standard deviation for each point, and the inter-assay coefficient of variation (CV) was < 10 %. d Antibody specificity determination using murine brain lysates and human CSF; Tg, WT and KO brain lysates were diluted to 5 μg/ml. Our assay permitted the direct quantification of native α-syn in biological samples such as human CSF and Tg mouse-brain lysates, whereas no signal was observed in WT or KO lysates. e Assessment of α-syn recovery rate in human CSF. The recovery rates were calculated from measured α-syn concentrations relative to spiked amounts, and the assay consistently featured a mean recovery rate > 90 %